يرجى استخدام متصفح الكمبيوتر الشخصي للوصول إلى التسجيل - تداول السعودية
حسنًا
Immunome reports net loss for 2025
Immunome, Inc. +2.48%
Immunome, Inc. IMNM | 21.86 | +2.48% |
Overview
Biotechnology company reported a net loss of $212.4 mln for full-year 2025
Company raised $460.5 mln in December 2025 public offering, extending cash runway into 2028
Result Drivers
Underwritten public offering in December 2025 raised $460.5 million in gross proceeds
Company press release: ID:nBw7055Nta
Key Details
Metric |
Beat/Miss |
Actual |
Consensus Estimate |
FY Net Income |
|
-$212.39 mln |
|
FY Income From Operations |
|
-$224.11 mln |
|
FY Operating Expenses |
|
$231.05 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Immunome Inc is $34.00, about 53.1% above its March 2 closing price of $22.21
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
